Combination of Failed Cancer Drugs and Checkpoint Inhibitors Offers Hope for New Treatment Approaches

A group of drugs known as checkpoint inhibitors has opened the door to hope for scientists to combat tumors, as researchers presented evidence that combining them with inhibitors of angiogenesis delays recurrence in liver cancer patients, which is the first treatment of its kind for this type of cancer.

And if the combination of these two drugs wins approval from the US Food and Drug Administration (FDA), it will be the eighth drug-type combination to be accepted in the past four years.

Researchers are currently conducting more than 200 clinical trials of this approach to treatment against different types of cancer, driven by evidence that angiogenesis inhibitors help cancer-fighting T cells penetrate deeper into tumors, says Robert Kerpel, an immuno-oncologist at the University of Toronto.

Using molecular techniques, the team of researchers created the CRISPR / Cas9 system that targets the closed circular DNA of the virus, which conventional drugs cannot detect, so that experts can test its action in artificial conditions in human cell culture, according to what the Russian Science Foundation told Sputnik.

The experiment showed that “molecular scissors” destroy more than 98 percent of the corresponding DNA molecules, while the CRISPR Cas9 complex itself disintegrates in one day, with scientists coming to the conclusion that if applied to the human body, it would not be able to damage non-target regions. in human DNA.